Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
06/2003
06/26/2003WO2002006327A3 A method for prognosing cancer and the proteins involved
06/26/2003WO2002004493A3 Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
06/26/2003WO2001057273A3 Human genome-derived single exon nucleic acid probes useful for analysis of gene expression in human adult liver
06/26/2003US20030121065 Polyfunctional base sequence and artificial gene containing the same
06/26/2003US20030121064 CNS neuroregenerative compositions and methods of use
06/26/2003US20030121061 Autoimmune diseases, antiinflamamtory agents, central nervous system disorders, vision defects, anticancer agenst
06/26/2003US20030120074 Cardioprotective phosphonates and malonates
06/26/2003US20030120059 Cell surface molecule-induced macrophage activation
06/26/2003US20030120053 Secreted and transmembrane polypeptides and nucleic acids encoding the same
06/26/2003US20030120052 Human genetic engineering; cancer diagnosis; hybrid nucleic acid
06/26/2003US20030120045 Immobilization onto polyoxyethylene glycol
06/26/2003US20030120039 Human preoptic regulatory factor-2 and uses thereof
06/26/2003US20030120038 Inhibitor of vascular endothelial cell growth factor
06/26/2003US20030120037 Complexing amyloid; modulating signal transduction
06/26/2003US20030120032 N-methyl-homocysteines and their use as well as process for their production
06/26/2003US20030119909 Stabilized medicament containing cysteinyl derivatives
06/26/2003US20030119891 Polylactam oligomers of N-methyl-2-carboxy-4-imidazole, N-methyl-2-carboxy-4-aminopyrrole modified by 4-aminobutyric acid, 3-amino-propionic acid and 3-(dimethylamino)propylamine binding specifically to the cyclogenase 2 gene
06/26/2003US20030119856 Thiazole compounds useful as inhibitors of protein kinase
06/26/2003US20030119807 Inhibit Procollagen C-proteinase; antiscarring treatment for wounds.
06/26/2003US20030119803 In particular N-epsilon-amino acid substituted L-lysine derivatives possessing aspartyl protease inhibitory properties.
06/26/2003US20030119797 Methods for selective immunomodulation
06/26/2003US20030119778 Novel gene useful for diagnosis and treatment of aplasia of corpus callosum and aspermatogenesis and use thereof
06/26/2003US20030119777 Oligoribonucleotides and ribonucleases for cleaving RNA
06/26/2003US20030119776 Synthetic oligonucleotide sequence of 2 to 10 bases; treating autoimmune encephalomyelitis, cancer, and graft rejection, tissue rejection or cell rejection.
06/26/2003US20030119775 Treating a disease or disorder associated with diminished UCP2 expression or activity, such as obesity, diabetes, syndrome X, or hypothermia, by administering an agent that enhances UCP2 expression
06/26/2003US20030119769 Antisense oligonucleotide modulation of raf gene expression
06/26/2003US20030119768 Reducing toxicity by treating the oligonucleotide in multimeric aggregate form to convert all of it to a monomeric form and to prevent the formation of aggregates before administration
06/26/2003US20030119767 Antisense modulation of NOD1 expression
06/26/2003US20030119766 Antisense modulation of apolipoprotein (A) expression
06/26/2003US20030119765 MDM2-specific antisense oligonucleotides
06/26/2003US20030119763 Compounds and methods for therapy and diagosis of lung cancer
06/26/2003US20030119752 Inhibiting particularly the activity of hepatitis C virus NS3-NS4A protease; peptidomimetics having a bridged bicyclic moiety at the P2 position.
06/26/2003US20030119751 Peptidomimetic; N-aminobutyl-N'-nitroguanidine derivatives
06/26/2003US20030119750 Use of dipeptidyl peptidase IV inhibitors
06/26/2003US20030119748 Use for treatment of inflammatory, autoimmune and neurodegenerative diseases, for the prevention of ischemic injury.
06/26/2003US20030119747 Methods of using pharmaceutical compositions comprising troponin subunits and homologs thereof before, during, or after surgical resection or radiologic ablation of a solid tumor
06/26/2003US20030119746 Treatment of both primary and metastatic solid tumors
06/26/2003US20030119745 Treatment of both primary and metastatic solid tumors
06/26/2003US20030119744 Treatment with Prostate Secretory Protein-94 led to a near normalization of plasma calcium and a marked reduction in PTHrP production
06/26/2003US20030119743 Pharmaceutical composition comprising factor VII polypeptides and tissue plasminogen inhibitors
06/26/2003US20030119741 Pharmaceutical composition comprising factor VII polypeptides and aprotinin polypeptides
06/26/2003US20030119740 Compositions and methods for the diagnosis, prevention and treatment of tumor progression
06/26/2003US20030119739 C-terminal globular domain of nidogen-1.
06/26/2003US20030119735 Delivery system
06/26/2003US20030119734 GLP-1(7-37) or an analogue wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer; pH is 7-10
06/26/2003US20030119733 Compositions and methods for inhibiting hepatocyte invasion by malarial sporozoites
06/26/2003US20030119732 CDDO-compounds and combination therapies thereof
06/26/2003US20030119731 Treating or preventing disorders associated with voltage gated ion channel disorders
06/26/2003US20030119729 Promoting survival of substantia nigra neuronal cells by contacting with a trophic amount of a ptc therapeutic; mimics hedgehog-mediated patched signal transduction; treating or preventing Parkinson's Disease
06/26/2003US20030119728 Stable, nasally, orally or sublingually applicable pharmaceutical preparation
06/26/2003US20030119727 FVIIa antagonists
06/26/2003US20030119726 P-glycoproteins and uses thereof
06/26/2003US20030119723 Useful in subjects who bleed excessively in association with surgery or major trauma
06/26/2003US20030119722 Process for purifying glycopeptide phosphonate derivatives
06/26/2003US20030119720 Oligopeptide treatment of anthrax
06/26/2003US20030119719 Use of endothelin conjugates in therapy, new endothelin conjugates, agents that contain the latter, and process for their production
06/26/2003US20030119715 Prevent retinoid binding; antiaging agents; activation cell differentiation
06/26/2003US20030119188 Novel compounds
06/26/2003US20030119183 Processes for the replication of influenza viruses in cell culture, and the influenza viruses obtainable by the process
06/26/2003US20030119168 Diagnosis of anticancer agents using nucleic acids
06/26/2003US20030119149 Fusion protein capable of forming a trimer; nonimmunogenic; modulates signaling of tumor necrosis family receptors
06/26/2003US20030119148 Amino-terminally truncated rantes as chemokine antagonists
06/26/2003US20030119147 Novel SLGP protein and nucleic acid molecules and uses therefor
06/26/2003US20030119144 Isolated human G-protein coupled receptors, nucleic acid molecules encoding human GPCR proteins, and uses thereof
06/26/2003US20030119135 Secreted and transmembrane polypeptides and nucleic acids encoding the same
06/26/2003US20030119128 Of given sequence; proteins used in modulating cell proliferation, inducing neovascularization and diagnosis of tumors
06/26/2003US20030119113 Fusion proteins; binding to antibodies
06/26/2003US20030119112 Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
06/26/2003US20030119111 G-protein coupled receptor, named 2871 receptor
06/26/2003US20030119103 Fusion proteins; binding to antibodies
06/26/2003US20030119102 Potassium channel interactors and uses therefor
06/26/2003US20030119097 Anticancer agents; screening genetic engineered libraries
06/26/2003US20030119096 Detect, calibration binding of galanin; therapy for nervous system disorders
06/26/2003US20030119095 Novel nucleic acid sequences encoding human vesicle transport protein-like and residue rat-like polypeptides
06/26/2003US20030119088 Phosphorylation of proteins; therapy for lysosome storage disease
06/26/2003US20030119081 Isolated nucleic acids; cancer diagnosis
06/26/2003US20030119078 Method of reducing immunogenicity of toxicity of an antibody of IgG class
06/26/2003US20030119076 B7-like polynucleotides, polypeptides, and antibodies
06/26/2003US20030119055 Secreted and transmembrane polypeptides and nucleic acids encoding the same
06/26/2003US20030119045 Controlling cell proliferation; adjust adhesion to substrate
06/26/2003US20030119038 NARC1, novel subtilase-like homologs
06/26/2003US20030119036 Isolated nucleic acids; anticholesterol agents, cardiovascular disorders, antiinflammatory agents, antilipemic agents
06/26/2003US20030119024 Measurement variations in gene expression; calibrating patterns
06/26/2003US20030119017 Anticancer agents, antiinflammatory agents, autoimmune disease; modulation of gene expression; nuclear factor kappa B
06/26/2003US20030119013 Identification of essential genes of Aspergillus fumigatus and methods of use
06/26/2003US20030119001 Secreted and transmembrane polypeptides and nucleic acids encoding the same
06/26/2003US20030118995 Novel Rab proteins
06/26/2003US20030118990 Novel estrogen-regulated G protein gamma subunit: compositions and methods of use
06/26/2003US20030118988 Brain and heart cyclic nucleotide gated ion channel compounds and uses thereof
06/26/2003US20030118660 Residual solvent extraction method and microparticles produced thereby
06/26/2003US20030118644 A solid forms comprising low molecular weight peptide-based thrombin inhibitor having pH dependent solubility, cellulose or starch as disintegrant fillers; immediate release
06/26/2003US20030118612 G-CSF conjugates
06/26/2003US20030118611 Epitopes confirmed to be recognized by T-cells derived from herpetic lesions or uterine cervix; vaccination
06/26/2003US20030118610 Oral delivery of peptides using enzyme-cleavable membrane translocators
06/26/2003US20030118605 Protein variants that exhibit reduced allergenicity when compared to the parental proteins; cosmetics
06/26/2003US20030118604 Comprising the 2-45 amino acid sequence of the N-terminal end of the core or nucleocapsid (p21) protein of the hepatitis C virus (HCV), excluding any protein or peptide compound comprising the N-terminal end
06/26/2003US20030118602 Peptides and immunologically functional variants thereof which are immunogenic epitopes recognized by CD8+ class I major histocompatibility complex restricted cytotoxic T-lymphocytes of patients harboring latent human cytomegalovirus infection
06/26/2003US20030118600 Transfer compounds, production and use thereof
06/26/2003US20030118599 Comprising lung tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cells that expresses such polypeptides, and T cells specific for cells expressing such polypeptides
06/26/2003US20030118598 Botulinum toxin pharmaceutical formulation free of animal derived proteins, comprising botulinum toxin and recombinant albumin, suitable for therapeutic administration to humans
1 ... 1821 1822 1823 1824 1825 1826 1827 1828 1829 1830 1831 1832 1833 1834 1835 1836 1837 1838 1839 1840 1841 ... 3163